Cisplatin (DDP) is the most effective drug for the treatment of human ovarian cancer, but the mechanisms that determine sensitivity to the cytotoxic action of DDP are not well understood. Treatment of two human ovarian carcinoma cell lines with epidermal growth factor (EGF) simultaneously increased sensitivity to DDP and caused a persistent change in morphology in the absence of any mitogenic effect. Sensitization to DDP was shown to be dependent on both EGF concentration and EGF receptor number in C127 mouse fibroblasts expressing the human EGF receptor after transfection with a pBPV plasmid construct containing the human EGF receptor gene under control of the transferrin receptor 3'-inducible regulator. Sensitization of human ovarian carcinoma cells to DDP was not blocked by inhibition of protein synthesis. EGF did not enhance sensitivity to DDP or alter morphology in DDP-resistant human ovarian carcinoma cells despite the presence of functional EGF receptors on these cells. These results showed that elements of the signal transduction pathway activated by EGF determined cellular sensitivity to DDP, and that a DDP-resistant phenotype is associated with a defect in this signal transduction pathway. Invest. 1990Invest. . 86:1632Invest. -1640 
Introduction
Platinum complexes, particularly cisplatin (DDP),' are drugs of major importance in cancer therapy. However, both intrinsic and acquired resistance to DDP occurs frequently. Cells selected for resistance to many antimetabolites (1) , and to drugs participating in the multiple drug resistance phenotype (2), often exhibit very high levels of resistance. In contrast, both in vitro and in vivo selection with DDP at clinically relevant intensities usually results in low-level resistant cells which are only two-to fourfold resistant to this drug (3) (4) (5) (6) . Attempts to enhance the sensitivity to DDP have focused on strategies such as reduction of glutathione (7) (8) (9) (10) and inhibition of DNA repair ( 1, 12) .
Binding of epidermal growth factor (EGF) to its receptor induces tyrosine phosphorylation of various cellular proteins including the EGF receptor itself. It has been exceedingly difficult to identify the key substrates that become phosphorylated besides the receptor itself, so the exact role of tyrosine phosphorylation in signal transduction remains uncertain. EGF receptor activation induces a variety of changes in intracellular physiology including activation of the Na+/H' transporter (13) , increase in calcium influx (14) , activation of glycolysis (15) , enhanced prostaglandin biosynthesis (16) , induction of ornithine decarboxylase and accumulation of putrescine (17) , changes in membrane potential (18) , inositol phosphate formation (19, 20) , activation of protein kinase C (21), S 6 ribosome phosphorylation (22) , oncogene expression (23) (24) (25) (26) (27) , stimulation of DNA synthesis (28) , and cell proliferation (28) .
We report here that activation of the receptor signal transduction pathway of the naturally occurring ligand EGF, can both enhance sensitivity to DDP, and produce morphologic changes consistent with activation of a differentiation program in two human ovarian carcinoma cell lines. While stimulation of DNA synthesis or cell proliferation are not required for EGF-induced sensitization to DDP, which of the many EGFinduced changes in cellular physiology are involved is currently not understood.
Methods
Cell lines and cell culture. Two well-characterized human ovarian carcinoma cell lines, designated 2008 (29) and COLO 316 (30) , and a DDP-resistant variant 2008/C13*, derived from the parent 2008 cell line (31) were used in these studies. The 10-fold DDP-resistant cell line 2008/C1 3* was generated by 13 monthly selections with 1 (38) .
Expression of the transferrin receptor gene is normally under the control of the transferrin receptor 3'-inducible regulator, and is regulated by iron (40) . Incubation with the iron chelator deferoxamine induces expression of the transferrin receptor gene (41) . To (35) (36) (37) .
Tetrazolium/formazan growth rate assay. Because C127 mouse fibroblasts do not form uniform colonies on plastic dishes, the sensitivity of control and deferoxamine-induced transfected C127 cells to DDP was compared by using a growth rate assay in which the cell number was quantified by tetrazolium dye reduction (42 The observed modulation of sensitivity to DDP by EGF was not due to an EGF-induced change in growth rate. The effect of both a 2-h exposure and continuous exposure to 10 nM EGF on growth rate was assayed using the same culture conditions under which EGF enhanced the sensitivity to DDP. During the first 5 d after cell seeding, cell growth was exponential. The doubling times of the 2008, 2008/C1 3*, and COLO 316 cells were 27.9, 28.2, and 29.2 h, respectively. Neither a 2-h nor a continuous exposure to 10 nM EGF had any demonstrable impact on the growth rate of these cell lines.
The effect of EGF on the sensitivity of 2008 cells to DDP was concentration dependent (Fig. 2) . Control cells were exposed to increasing concentrations of EGF alone. EGF-and DDP-treated cells were exposed to EGF at increasing concentrations combined with DDP at a fixed concentration of 2 gM. First, the cells were exposed to EGF for 1 h, and then to both EGF and DDP concurrently during the second hour. A 2-h exposure to EGF (1 h before and 1 h concurrent with DDP) enhanced sensitivity to DDP at EGF concentrations as low as 0.4 nM, and the effect was maximal at concentrations of -10 nM (approximately four times the Kd of the EGF receptor). As expected, a further increase in the EGF concentration up to 100 nM produced no additional change in sensitivity to DDP. The data presented in Fig. 2 is consistent with saturation of EGF binding at EGF concentrations over 10 nM, or with the presence oftwo distinct cell populations ofwhich one is totally unresponsive to EGF. The latter possibility has not been formally excluded. (Fig. 3) .
In addition to enhancing sensitivity to DDP, and despite the lack of effect on growth, a 2-h exposure to (37, 44) . By demonstrating receptor down-regulation of the human EGF receptors expressed on transfected C 127 cells upon binding of EGF, it can be inferred that these receptors are functional, i.e., capable of receptor autophosphorylation (vide supra). The sensitivity of control and deferoxamine-induced cells to DDP was compared by using a growth rate assay in which the cell number was quantitated by tetrazolium dye reduction (42) . Fig. 5 shows that, in the presence of 10 nM EGF, the deferoxamine-treated cells were approximately twofold more sensitive to DDP than control cells. Deferoxamine at a concentration of 10 (45, 46) . In this model it has been convincingly shown that receptor autophosphorylation, and thus protein tyrosine kinase activity, are essential for signal transduction and for receptor down-regulation secondary to binding of EGF to its receptor (45, 46 (49) .
We have recently shown that activation of two other signal transduction pathways involving protein kinase A and protein kinase C can modulate the sensitivity to DDP in human ovarian carcinoma cells (50, 51) . Stimulation of protein kinase A by forskolin increased the sensitivity to DDP by increasing drug accumulation (50) . Similar to EGF, forskolin failed to enhance sensitivity to DDP in DDP-resistant 2008/C1 3* cells. Stimulation of protein kinase C by the tumor promoter TPA increased the sensitivity of 2008 cells by 2.5-fold (51) . Thus, activation of at least three different signal transduction pathways including protein kinase A, protein kinase C, and the EGF receptor can modulate sensitivity to DDP in human ovarian carcinoma cells. It is conceivable that the final target mediating sensitization to DDP is the same in all three pathways. Recently, exposure of CaSki human squamous carcinoma cells to EGF was shown to enhance radiosensitivity (52). It is currently not known whether there is a single element of the EGF signal transduction pathway capable of regulating both radiosensitivity and sensitivity to DDP, or whether different elements of the pathway are independently mediating these two effects.
Even though EGF induced only a two-to threefold increase in sensitivity to DDP, this change may be clinically significant. Several investigators have reported that patients pretreated with DDP had low-level resistance to DDP, and that human ovarian carcinoma cell lines derived from the patients' tumor at the time the tumor became unresponsive to DDP were only two-to fourfold resistant to DDP (3) (4) (5) (6) . In several in vivo murine models, DDP-resistant cell lines could be isolated from tumors treated with as few as two doses of DDP (53, 54) . The level of resistance found in these animal studies was also low-lpvel, in the range of two-to fourfold (53, 54) . Taken together, these studies in the human and in animals indicate that in vivo low levels of resistance to DDP appear rapidly and are sufficient for treatment failure. Therefore, a two-to threefold increase in sensitivity to DDP, as observed in EGF-treated cells, is potentially clinically significant. Furthermore, several types of human tumors are known to express unusually large numbers of EGF receptors in vivo (55) (56) (57) (58) (59) , and we speculate that EGF may be used to selectively enhance the DDP sensitivity of these tumors without increasing the toxicity of DDP to normal tissues. This may be facilitated by the fact that the number of EGF receptors can be increased by a variety of agents available for clinical use such. as retinoic acid (60) , estrogen (61) , progesterone (62) , triiodothyronine (63), and androgens (64) . Furthermore, EGF may be used to stimulate differentiation of ovarian carcinomas, thus potentially reducing the degree of malignancy. To fully comprehend the biological significance of our findings, many cell lines from different tissues will have to be screened for EGF-induced sensitization to DDP, and the effect of EGF on sensitivity to DDP and potential induction of a differentiation program will need to be studied in the in vivo animal model.
